Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03949231 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 1, 2025 to Jan 1, 2029
    • Study completion date: Jan 2, 2028 to Jan 2, 2038
    • Study description expanded, about 3 words
    • Study title shortened, about 3 words
    v6
  2. Primary completion date: Jan 1, 2022 to Jan 1, 2025
    • Study completion date: Jan 2, 2022 to Jan 2, 2028
    v5
  3. Site contact updatedv4
  4. Interventions: Toripalimab (Drug) to PD1/PDL1 inhibitor (Drug)
    • Study description shortened, about 1 word
    • Study title expanded, about 1 word
    v3
  5. Primary completion date: Jan 1, 2021 to Jan 1, 2022
    • Study completion date: Jan 2, 2021 to Jan 2, 2022
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Trial Details
NCT Number NCT03949231
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Liver Cancer
Related terms Liver Neoplasms
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov